European CHMP recommends approval of entrectinib (Rozlytrek) for treatment of advanced solid tumours and non-small cell lung cancer (NSCLC)

Entrectinib is a tropomyosin receptor kinase inhibitor reported to increase objective response rate and response duration in locally advanced, metastatic solid tumours that display a NTRK gene fusion, and in ROS1-positive advanced NSCLC.


European Medicines Agency